Asher Bio is initially applying our cis-targeting platform to make a quantum leap with cytokine immunotherapies.

These cytokines are clinically validated immunotherapies, but their use is severely limited due to toxicity, and their efficacy is hindered by non-specific activation of various immune cell types. Cytokines are an ideal focus for cis-targeting because of their inherent pleiotropy. Cis-targeting has the potential to broaden the therapeutic window, offering improvements in both efficacy and safety.

Our near-term focus is on the outstanding potential of AB248, a cis-targeted IL-2 immunotherapy.

As a potential best-in-class interleukin-2 (IL-2) immunotherapy, we are developing AB248 to address multiple solid tumor indications as monotherapy and in combination with checkpoint inhibitors. Further expansion of AB248 may include applications in cell therapy and in the treatment of certain infectious diseases.

Beyond AB248, Asher Bio is applying our modular toolkit to develop cis-targeted immunotherapies that leverage our discoveries in IL-2 and other cis-targeted cytokines for use in oncology, as well as autoimmune and infectious diseases.

 

LEARN ABOUT AB248, OUR CD8+ CIS-TARGETED IL-2 THERAPY

Our lead cis-targeted immunotherapy, AB248, selectively activates the IL-2 receptor pathway on CD8+ T cells and has shown highly-compelling preclinical efficacy.

AB248

 
 

This links to an external website.

Continue